A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Public ClinicalTrials.gov record NCT01217957. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Second-Generation Proteasome Inhibitor, Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Study identification
- NCT ID
- NCT01217957
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Enrollment
- 65 participants
Conditions and interventions
Conditions
Interventions
- Ixazomib Drug
- Lenalidomide Drug
- Dexamethasone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2010
- Primary completion
- Mar 7, 2013
- Completion
- Feb 1, 2018
- Last update posted
- Mar 13, 2018
2010 – 2018
United States locations
- U.S. sites
- 16
- U.S. states
- 15
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Scottsdale | Arizona | 85259 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| Rocky Mountain Cancer Center Rose | Denver | Colorado | 80218 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06489 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Mt Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Harry and Jeannette Weinberg Cancer Center at Franklin Square Hospital | Baltimore | Maryland | 21215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| New York Presbyterian Hospital - Weill-Cornell | New York | New York | 10021 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| W VA University Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
| The Medical College of Wisconsin, Inc. | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01217957, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 13, 2018 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01217957 live on ClinicalTrials.gov.